Genetically engineered cerebral organoids model brain tumor formation.
Bian S, Repic M, Guo Z, Kavirayani A, Burkard T, Bagley JA, Krauditsch C, Knoblich JA.
Nat Methods. 2018 Aug;15(8):631-639. doi: 10.1038/s41592-018-0070-7. Epub 2018 Jul 23.
Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.
Moody TW, Lee L, Ramos-Alvarez I, Iordanskaia T, Mantey SA, Jensen RT.
Front Endocrinol (Lausanne). 2021 Sep 1;12:728088. doi: 10.3389/fendo.2021.728088. eCollection 2021.
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, Bloomquist EW, Charlab R, Hamed SS, Miller CP, Dorff SE, Chambers WA, Mixter BD, Dinin J, Pierce WF, Ricks TK, Tang S, Donoghue M, Pazdur R, Amiri-Kordestani L, Ibrahim A, Beaver JA.
Clin Cancer Res. 2022 Nov 14;28(22):4843-4848. doi: 10.1158/1078-0432.CCR-22-1054.
Primitive Neuroectodermal Tumor.
Rios CI, De Jesus O.
2023 Aug 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification.
Keck MK, Sill M, Wittmann A, Joshi P, Stichel D, Beck P, Okonechnikow K, Sievers P, Wefers AK, Roncaroli F, Avula S, McCabe MG, Hayden JT, Wesseling P, Øra I, Nistér M, Kranendonk MEG, Tops BBJ, Zapotocky M, Zamecnik J, Vasiljevic A, Fenouil T, Meyronet D, von Hoff K, Schüller U, Loiseau H, Figarella-Branger D, Kramm CM, Sturm D, Scheie D, Rauramaa T, Pesola J, Gojo J, Haberler C, Brandner S, Jacques T, Sexton Oates A, Saffery R, Koscielniak E, Baker SJ, Yip S, Snuderl M, Ud Din N, Samuel D, Schramm K, Blattner-Johnson M, Selt F, Ecker J, Milde T, von Deimling A, Korshunov A, Perry A, Pfister SM, Sahm F, Solomon DA, Jones DTW.
Acta Neuropathol. 2023 Jan;145(1):49-69. doi: 10.1007/s00401-022-02516-2. Epub 2022 Nov 27.
Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials.
Liu APY, Dhanda SK, Lin T, Sioson E, Vasilyeva A, Gudenas B, Tatevossian RG, Jia S, Neale G, Bowers DC, Hassall T, Partap S, Crawford JR, Chintagumpala M, Bouffet E, McCowage G, Broniscer A, Qaddoumi I, Armstrong G, Wright KD, Upadhyaya SA, Vinitsky A, Tinkle CL, Lucas J, Chiang J, Indelicato DJ, Sanders R, Klimo P Jr, Boop FA, Merchant TE, Ellison DW, Northcott PA, Orr BA, Zhou X, Onar-Thomas A, Gajjar A, Robinson GW.
Acta Neuropathol. 2022 Oct;144(4):733-746. doi: 10.1007/s00401-022-02484-7. Epub 2022 Aug 18.
Considerations for the Use of SH-SY5Y Neuroblastoma Cells in Neurobiology.
Kovalevich J, Santerre M, Langford D.
Methods Mol Biol. 2021;2311:9-23. doi: 10.1007/978-1-0716-1437-2_2.
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.
Levy AS, Krailo M, Chi S, Villaluna D, Springer L, Williams-Hughes C, Fouladi M, Gajjar A.
Pediatr Blood Cancer. 2021 Aug;68(8):e29031. doi: 10.1002/pbc.29031. Epub 2021 Apr 12.
Central nervous system (CNS) neuroblastoma. A case-based update.
Bianchi F, Tamburrini G, Gessi M, Frassanito P, Massimi L, Caldarelli M.
Childs Nerv Syst. 2018 May;34(5):817-823. doi: 10.1007/s00381-018-3764-3. Epub 2018 Mar 8.
Primitive neuroectodermal tumors of the central nervous system.
Rorke LB, Trojanowski JQ, Lee VM, Zimmerman RA, Sutton LN, Biegel JA, Goldwein JW, Packer RJ.
Brain Pathol. 1997 Apr;7(2):765-84. doi: 10.1111/j.1750-3639.1997.tb01063.x.
